Celea Therapeutics raised $180 million to advance the development of deupirfenidone, a deuterated form of the FDA-approved therapy pirfenidone, into a Phase 3 head-to-head superiority trial for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive lung disease.
